BioTime CEO Dr. Michael West to Present at Stem Cells USA & Regenerative Medicine Congress 2009

ALAMEDA, Calif.--(Business Wire)--
BioTime, Inc. (NYSE Amex: BTIM) Chief Executive Officer Michael West, Ph.D. will
give two presentations at the Stem Cells USA & Regenerative Medicine Congress
2009 to be held at The Westin Washington DC City Center Hotel in Washington, DC
from November 16-18, 2009. On Tuesday, November 17, Dr. West will discuss
applications of stem cell technology for diseases of the skin and bone. Dr. West
will provide an update on BioTime`s ACTCellerate technology platform in
cartilage biology and will disclose new data from the Company`s fate space
screen. Then on Wednesday, November 18, Dr. West will give a presentation during
a panel session discussing business models for regenerative medicine. Both
presentations will be made available on the Company's website at
www.biotimeinc.com.

About BioTime, Inc.

BioTime, headquartered in Alameda, California, is a biotechnology company
focused on regenerative medicine and blood plasma volume expanders. BioTime
develops and markets research products in the field of stem cells and
regenerative medicine through its wholly owned subsidiary Embryome Sciences,
Inc. BioTime`s subsidiary OncoCyte Corporation focuses on the therapeutic
applications of stem cell technology in cancer. BioTime also plans to develop
therapeutic products in China for the treatment of ophthalmologic, skin,
musculo-skeletal system and hematologic diseases, including the targeting of
genetically modified stem cells to tumors as a novel means of treating currently
incurable forms of cancer through its subsidiary BioTime Asia. In addition to
its stem cell products, BioTime markets blood plasma volume expanders and
related technology for use in surgery, emergency trauma treatment, and other
applications. BioTime's lead product, Hextend®, is a blood plasma volume
expander manufactured and distributed in the U.S. by Hospira, Inc. and in South
Korea by CJ CheilJedang Corp. under exclusive licensing agreements. Additional
information about BioTime can be found on the web at www.biotimeinc.com.
ACTCellerate is a trademark licensed to Embryome Sciences, Inc. by Advanced Cell
Technology, Inc.

Forward-Looking Statements

Statements pertaining to future financial and/or operating results, future
growth in research, technology, clinical development and potential opportunities
for the company and its subsidiaries, along with other statements about the
future expectations, beliefs, goals, plans, or prospects expressed by management
constitute forward-looking statements. Any statements that are not historical
fact (including, but not limited to statements that contain words such as
"will," "believes," "plans," "anticipates," "expects," "estimates,") should also
be considered to be forward-looking statements. Forward-looking statements
involve risks and uncertainties, including, without limitation, risks inherent
in the development and/or commercialization of potential products, uncertainty
in the results of clinical trials or regulatory approvals, need and ability to
obtain future capital, and maintenance of intellectual property rights. Actual
results may differ materially from the results anticipated in these
forward-looking statements and as such should be evaluated together with the
many uncertainties that affect the company's business, particularly those
mentioned in the cautionary statements found in the company's Securities and
Exchange Commission filings. The company disclaims any intent or obligation to
update these forward-looking statements.

To receive ongoing BioTime corporate communications, please click on the
following link to join our email alert list:
http://www.b2i.us/irpass.asp?BzID=1152&to=ea&s=0

BioTime, Inc.
Judith Segall, 510-521-3390, ext 301
jsegall@biotimemail.com

Copyright Business Wire 2009